RAD51C and breast cancer: Germline and somatic alterations in HR genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas [137], and there are clinical trials that are evaluating the efficacy of PARP inhibitors in patients with germline RAD51C/D variants and metastatic BC [136].